SEARCH

SEARCH BY CITATION

References

  • 1
    Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81, 741766.
  • 2
    Hardy JA & Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184185.
  • 3
    Terry RD, Maslia E & Hansen LA (1999) The neuropathology of Alzheimer disease and the structural basis of its cogninitve alterations. In Alzheimer Disease (Terry RD, Katzman R, Bick KL & Sisodia SS eds), pp 187206. Lipponcott Williams and Wilikins, Philadelphia.
  • 4
    Caughey B & Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267298.
  • 5
    Haass C & Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101112.
  • 6
    Laferla FM, Green KN & Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8, 499509.
  • 7
    Klein WL, Krafft GA & Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24, 219224.
  • 8
    Chiti F & Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75, 333366.
  • 9
    Ferreira ST, Vieira MN & De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases. IUBMB Life 59, 332345.
  • 10
    Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 2963929643.
  • 11
    Roychaudhuri R, Yang M, Hoshi MM & Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284, 47494753.
  • 12
    Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 64486453.
  • 13
    Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M & Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352357.
  • 14
    Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ & Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535539.
  • 15
    Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA et al. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133140.
  • 16
    Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB & Selkoe DJ (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270, 95649570.
  • 17
    Walsh DM, Tseng BP, Rydel RE, Podlisny MB & Selkoe DJ (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 1083110839.
  • 18
    Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea J-E, Ruotolo BT, Robinson CV et al. (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer’s disease. Nat Chem 1, 326331.
  • 19
    Ono K, Condron MM & Teplow DB (2009) Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106, 1474514750.
  • 20
    Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 103, 51615166.
  • 21
    Lefterov I, Fitz NF, Cronican A, Lefterov P, Staufenbiel M & Koldamova R (2009) Memory deficits in APP23/Abca1+/- mice correlate with the level of Abeta oligomers. ASN Neuro 1, e00006.
  • 22
    Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ & Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271, 40774081.
  • 23
    Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA & Holzman TF (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67, 12161228.
  • 24
    Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE & Klein WL (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79, 595605.
  • 25
    Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB & Teplow DB (2003) Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100, 330335. Epub 2002 Dec 2027.
  • 26
    Lashuel HA & Lansbury PT Jr (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39, 167201.
  • 27
    Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N & Sato K (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci USA 100, 63706375.
  • 28
    Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW & Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • 29
    Necula M, Kayed R, Milton S & Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282, 1031110324.
  • 30
    Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P & Smith SO (2006) High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 358, 106119.
  • 31
    Losic D, Martin LL, Mechler A, Aguilar MI & Small DH (2006) High resolution scanning tunnelling microscopy of the beta-amyloid protein (Abeta1-40) of Alzheimer’s disease suggests a novel mechanism of oligomer assembly. J Struct Biol 155, 104110.
  • 32
    Ding H, Wong PT, Lee EL, Gafni A & Steel DG (2009) Determination of the oligomer size of amyloidogenic protein beta-amyloid(1-40) by single-molecule spectroscopy. Biophys J 97, 912921.
  • 33
    Dukes KD, Rodenberg CF & Lammi RK (2008) Monitoring the earliest amyloid-beta oligomers via quantized photobleaching of dye-labeled peptides. Anal Biochem 382, 2934.
  • 34
    Garai K, Sengupta P, Sahoo B & Maiti S (2006) Selective destabilization of soluble amyloid beta oligomers by divalent metal ions. Biochem Biophys Res Commun 345, 210215.
  • 35
    Orte A, Birkett NR, Clarke RW, Devlin GL, Dobson CM & Klenerman D (2008) Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Natl Acad Sci USA 105, 1442414429.
  • 36
    Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M & Yanagisawa K (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282, 26462655.
  • 37
    Yanagisawa K (2007) Role of gangliosides in Alzheimer’s disease. Biochim Biophys Acta 1768, 19431951.
  • 38
    Stege GJ, Renkawek K, Overkamp PS, Verschuure P, van Rijk AF, Reijnen-Aalbers A, Boelens WC, Bosman GJ & de Jong WW (1999) The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem Biophys Res Commun 262, 152156.
  • 39
    Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136, 2231.
  • 40
    Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P et al. (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 1274912760.
  • 41
    Coulson EJ (2006) Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer’s disease? J Neurochem 98, 654660.
  • 42
    Dechant G & Barde YA (2002) The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci 5, 11311136.
  • 43
    Costantini C, Della-Bianca V, Formaggio E, Chiamulera C, Montresor A & Rossi F (2005) The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta-amyloid. Exp Cell Res 311, 126134.
  • 44
    Zhang Y, Hong Y, Bounhar Y, Blacker M, Roucou X, Tounekti O, Vereker E, Bowers WJ, Federoff HJ, Goodyer CG et al. (2003) p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 23, 73857394.
  • 45
    De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST & Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 1159011601.
  • 46
    Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ & Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 28662875.
  • 47
    De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST & Klein WL (2009) Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106, 19711976.
  • 48
    Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA & Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246260.
  • 49
    Townsend M, Mehta T & Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282, 3330533312.
  • 50
    Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J & Ferreira ST (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283, 93599368.
  • 51
    Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, Hillen H, Gross G, Ebert U & Bruehl C (2008) Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 28, 788797.
  • 52
    Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, Sokolov Y, Hall JE & Losche M (2008) Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys J 95, 48454861.
  • 53
    Kawahara M & Kuroda Y (2000) Molecular mechanism of neurodegeneration induced by Alzheimer’s beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull 53, 389397.
  • 54
    Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4, 4960.
  • 55
    Lauren J, Gimbel DA, Nygaard HB, Gilbert JW & Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 11281132.
  • 56
    Mandal PK, Pettegrew JW, Masliah E, Hamilton RL & Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 31, 11531162.
  • 57
    Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M & Mucke L (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 98, 1224512250.
  • 58
    Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O et al. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS ONE 3, e3135.
  • 59
    Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC & Hyman BT (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116, 33393346.
  • 60
    Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T et al. (1997) An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease. Nature 389, 689695.
  • 61
    Almeida CG, Takahashi RH & Gouras GK (2006) Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 26, 42774288.
  • 62
    Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ & Mook-Jung I (2005) Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev 126, 12921299.
  • 63
    Tseng BP, Green KN, Chan JL, Blurton-Jones M & LaFerla FM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29, 16071618.
  • 64
    Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D’Andrea MR, Dinsmore S & Nagele RG (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223236.
  • 65
    Nixon RA (2006) Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci 29, 528535.
  • 66
    Yang AJ, Chandswangbhuvana D, Margol L & Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52, 691698.
  • 67
    Yuyama K, Yamamoto N & Yanagisawa K (2008) Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. J Neurochem 105, 217224.
  • 68
    Sakono M, Zako T, Ueda H, Yohda M & Maeda M (2008) Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. Febs J 275, 59825993.
  • 69
    Hartl FU & Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 18521858.
  • 70
    Vainberg IE, Lewis SA, Rommelaere H, Ampe C, Vandekerckhove J, Klein HL & Cowan NJ (1998) Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 93, 863873.
  • 71
    Zako T, Iizuka R, Okochi M, Nomura T, Ueno T, Tadakuma H, Yohda M & Funatsu T (2005) Facilitated release of substrate protein from prefoldin by chaperonin. FEBS Lett 579, 37183724.
  • 72
    Zako T, Murase Y, Iizuka R, Yoshida T, Kanzaki T, Ide N, Maeda M, Funatsu T & Yohda M (2006) Localization of prefoldin interaction sites in the hyperthermophilic group II chaperonin and correlations between binding rate and protein transfer rate. J Mol Biol 364, 110120.
  • 73
    Okochi M, Nomura T, Zako T, Arakawa T, Iizuka R, Ueda H, Funatsu T, Leroux M & Yohda M (2004) Kinetics and binding sites for interaction of the prefoldin with a group II chaperonin: contiguous non-native substrate and chaperonin binding sites in the archaeal prefoldin. J Biol Chem 279, 3178831795.
  • 74
    Macario AJ & Conway de Macario E (2005) Sick chaperones, cellular stress, and disease. N Engl J Med 353, 14891501.
  • 75
    Muchowski PJ & Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6, 1122.
  • 76
    Powers ET, Morimoto RI, Dillin A, Kelly JW & Balch WE (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78, 959991.
  • 77
    Tam S, Geller R, Spiess C & Frydman J (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8, 11551162.
  • 78
    Kitamura A, Kubota H, Pack CG, Matsumoto G, Hirayama S, Takahashi Y, Kimura H, Kinjo M, Morimoto RI & Nagata K (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 8, 11631170.
  • 79
    Behrends C, Langer CA, Boteva R, Bottcher UM, Stemp MJ, Schaffar G, Rao BV, Giese A, Kretzschmar H, Siegers K et al. (2006) Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 23, 887897.
  • 80
    Zhang Y, McLaughlin R, Goodyer C & LeBlanc A (2002) Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156, 519529.
  • 81
    Chui DH, Dobo E, Makifuchi T, Akiyama H, Kawakatsu S, Petit A, Checler F, Araki W, Takahashi K & Tabira T (2001) Apoptotic neurons in Alzheimer’s disease frequently show intracellular Abeta42 labeling. J Alzheimers Dis 3, 231239.
  • 82
    Mousnier A, Kubat N, Massias-Simon A, Segeral E, Rain JC, Benarous R, Emiliani S & Dargemont C (2007) von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc Natl Acad Sci USA 104, 1361513620.
  • 83
    Sorgjerd K, Klingstedt T, Lindgren M, Kagedal K & Hammarstrom P (2008) Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 377, 10721078.